{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:00:08Z","timestamp":1785157208474,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>BRCA1\/2 alterations have emerged as clinically relevant biomarkers in prostate cancer because of their prognostic significance and predictive value for response to poly(ADP-ribose) polymerase inhibitors. As indications for molecular testing expand, histopathologists play a pivotal role in ensuring the quality and reliability of somatic BRCA testing. This narrative review provides a histopathologist-oriented overview of the principal pre-analytical, technical, and morphological issues influencing BRCA testing in PC, with emphasis on tissue selection, specimen processing, nucleic acid preservation, and genotype\u2013phenotype correlations. The success of somatic BRCA testing depends on several pre-analytical variables, including fixation, storage time, tumor cellularity (generally \u226510\u201320% neoplastic cells for reliable NGS analysis), specimen type, and DNA quality. Bone metastasis specimens require special attention because decalcification procedures may compromise nucleic acid integrity and molecular testing performance. From a morphological perspective, BRCA-associated PCs, especially those harboring BRCA2 alterations, are characterized by adverse clinicopathological features, including a higher grade and stage at diagnosis. Although intraductal carcinoma of the prostate and cribriform architecture are associated with genomic instability and poor prognosis, their value as surrogate markers of BRCA1\/2 alterations remains uncertain. Histopathologists play a central role in optimizing BRCA testing through appropriate specimen selection, tissue handling, and multidisciplinary collaboration, thereby supporting precision medicine in prostate cancer.<\/jats:p>","DOI":"10.3390\/diagnostics16152358","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:54:26Z","timestamp":1785153266000},"page":"2358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BRCA Testing in Prostate Cancer: A Histopathologist\u2019s Perspective"],"prefix":"10.3390","volume":"16","author":[{"given":"Francesca","family":"Sanguedolce","sequence":"first","affiliation":[{"name":"Unit of Pathology, Department of Clinical and Experimental Medicine, University of Foggia, Policlinico Riuniti, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3058-4110","authenticated-orcid":false,"given":"Roberta","family":"Mazzucchelli","sequence":"additional","affiliation":[{"name":"Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health, United Hospitals, Universit\u00e0 Politecnica delle Marche, 60131 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology and CREATE Center for Research and Innovation Medicine, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3158","authenticated-orcid":false,"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Center, IRCCS San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","unstructured":"IARC (2026, June 03). Global Cancer Observatory: Cancer Today. Available online: https:\/\/gco.iarc.who.int\/en."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer","volume":"86","author":"Cornford","year":"2026","journal-title":"Eur. Assoc. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/jmg-2024-109845","article-title":"Genetics of prostate cancer: A review of latest evidence","volume":"61","author":"Hall","year":"2024","journal-title":"J. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41391-023-00676-0","article-title":"Guidelines for genetic testing in prostate cancer: A scoping review","volume":"27","author":"Tuffaha","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mammone, G., Borghesi, S., Borsellino, N., Cali\u00f2, A., Ceccarelli, R., Cimadamore, A., Conti, G.N., Cortesi, L., D\u2019Angelillo, R.M., and Facchini, G. (2025). Integrating BRCA testing into routine prostate cancer care: A multidisciplinary approach by SIUrO and other Italian Scientific Societies. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13521-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline Mutations in ATM and BRCA1\/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death","volume":"71","author":"Na","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chen, J.Y., Wang, P.Y., Liu, M.Z., Lyu, F., Ma, M.W., Ren, X.Y., and Gao, X.S. (2023). Biomarkers for Prostate Cancer: From Diagnosis to Treatment. Diagnostics, 13.","DOI":"10.3390\/diagnostics13213350"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Valsecchi, A.A., Dionisio, R., Panepinto, O., Paparo, J., Palicelli, A., Vignani, F., and Di Maio, M. (2023). Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15092435"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","unstructured":"NCCN (2026). Clinical Practice Guidelines in Oncology. Prostate Cancer\u2014Version 5.2026. J. Natl. Compr. Canc. Netw., 24, 140\u2013149."},{"key":"ref_14","unstructured":"NCCN (2026). Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate\u2014Version 3.2026. J. Natl. Compr. Canc. Netw., 24, 2\u201310."},{"key":"ref_15","unstructured":"AIOM (2024). Linee Guida AIOM; Carcinoma della Prostata, AIOM."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/ajco.14150","article-title":"BRCA Mutation Testing in Men with Metastatic Castration-Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice","volume":"21","author":"Azad","year":"2025","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155803","DOI":"10.1016\/j.prp.2024.155803","article-title":"BRCA1 and BRCA2 mutations testing in prostate cancer: Detection in formalin fixed paraffin embedded (FFPE) and blood samples","volume":"266","author":"Zannini","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tsantikidi, A., Papadopoulou, E., Metaxa-Mariatou, V., Kapetsis, G., Tsaousis, G., Meintani, A., Florou-Chatzigiannidou, C., Gazouli, M., Papadimitriou, C., and Timotheadou, E. (2023). The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking. Diagnostics, 13.","DOI":"10.20944\/preprints202307.0781.v1"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Antolini, E., Filosa, A., Santoni, M., Antaldi, E., Bartoli, E., Sierchio, L., Giantomassi, F., Mandolesi, A., and Goteri, G. (2024). Internal Overview of Prostatic Cancer Cases and Quality of BRCA1 and BRCA2 NGS Data from the FFPE Tissue. Diagnostics, 14.","DOI":"10.3390\/diagnostics14182067"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.23484","article-title":"Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","volume":"78","author":"Silberstein","year":"2018","journal-title":"Prostate"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","article-title":"Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer","volume":"147","author":"Lozano","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"110987","DOI":"10.1016\/j.urolonc.2025.110987","article-title":"Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer","volume":"44","author":"Watanabe","year":"2026","journal-title":"Urol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100459","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: A position paper of Italian Scientific Societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Vescovo, M., Raspollini, M.R., Nibid, L., Castiglione, F., Nardi, E., de Biase, D., Massari, F., Giunchi, F., Pepe, F., and Troncone, G. (2025). Storage Time and DNA Quality Determine BRCA1\/2 Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications. Cancers, 17.","DOI":"10.3390\/cancers17101705"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.32074\/1591-951X-1010","article-title":"BRCA testing in metastatic castration-resistant prostate cancer: Successes and troubles in a real world setting. An Italian Multicentric study","volume":"116","author":"Tommasi","year":"2024","journal-title":"Pathologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Angerilli, V., Galuppini, F., Pagni, F., Fusco, N., Malapelle, U., and Fassan, M. (2021). The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020339"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cappello, F., Angerilli, V., Munari, G., Ceccon, C., Sabbadin, M., Pagni, F., Fusco, N., Malapelle, U., and Fassan, M. (2022). FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. J. Pers. Med., 12.","DOI":"10.3390\/jpm12050750"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.18632\/oncotarget.28015","article-title":"Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): Challenges and solutions","volume":"12","author":"Scott","year":"2021","journal-title":"Oncotarget"},{"key":"ref_30","unstructured":"AIOM (2023). Raccomandazioni AIOM per L\u2019implementazione Dell\u2019analisi Delle Varianti Patogenetiche di BRCA Nei Pazienti Con Carcinoma Della Prostata Metastatico, AIOM. Version 2.0."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5489\/cuaj.8588","article-title":"2023 Canadian Urological Association guideline: Genetic testing in prostate cancer","volume":"17","author":"Rendon","year":"2023","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"oyaf395","DOI":"10.1093\/oncolo\/oyaf395","article-title":"Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: A multicenter cohort study","volume":"30","author":"Incorvaia","year":"2025","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00081","article-title":"Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy","volume":"3","author":"Velho","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pathol.2020.10.003","article-title":"Molecular pathology of prostate cancer: A practical approach","volume":"53","author":"Vlajnic","year":"2021","journal-title":"Pathology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00327","article-title":"Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations","volume":"3","author":"Schweizer","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/his.13806","article-title":"DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features","volume":"74","author":"Lotan","year":"2019","journal-title":"Histopathology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Han, H., Park, C.K., Cho, N.H., Lee, J., Jang, W.S., Ham, W.S., Choi, Y.D., and Cho, K.S. (2022). Characteristics of BRCA2 Mutated Prostate Cancer at Presentation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113426"},{"key":"ref_38","unstructured":"Zhou, M., Netto, G.J., Fine, S.W., Leite, K.R.M., Lotan, T.L., Varma, M., and Egevad, L. (2022). Intraductal carcinoma of the prostate. WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours, International Agency for Research on Cancer. [5th ed.]. Available online: https:\/\/tumourclassification.iarc.who.int\/chapters\/36."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e6939","DOI":"10.1002\/cam4.6939","article-title":"Molecular complexity of intraductal carcinoma of the prostate","volume":"13","author":"Zhu","year":"2024","journal-title":"Cancer Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00428-019-02544-6","article-title":"Intraductal carcinoma of the prostate: A critical re-appraisal","volume":"474","author":"Varma","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_42","first-page":"1869","article-title":"Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies","volume":"40","author":"Grypari","year":"2025","journal-title":"Histol. Histopathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106018","DOI":"10.1016\/j.humpath.2025.106018","article-title":"Updates in bladder and prostate pathology: Diagnostic consensus and clinical relevance","volume":"169","author":"Collins","year":"2026","journal-title":"Hum. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/his.70046","article-title":"The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate","volume":"88","author":"Shah","year":"2026","journal-title":"Histopathology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.humpath.2024.01.005","article-title":"Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway","volume":"144","author":"Mahlow","year":"2024","journal-title":"Hum. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lee, S., Park, I., Ahn, B., Lim, B., Kim, J.K., You, D., Jeong, I.G., Hong, J.H., Ahn, H., and Suh, J. (2025). Evaluation of intraductal carcinoma and invasive cribriform carcinoma as predictors of genetic mutations in systemic treatment-na\u00efve prostate cancer patients. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15001-2"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Bernhardt, M., and Kristiansen, G. (2023). Molecular Alterations in Intraductal Carcinoma of the Prostate. Cancers, 15.","DOI":"10.3390\/cancers15235512"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/15\/2358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:07:33Z","timestamp":1785154053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/15\/2358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":47,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["diagnostics16152358"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16152358","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}